SCHEMBL4335595

SCHEMBL4335595

CC(C)OC(Cc1cn(CCOC(=O)Nc2cccc(C(F)(F)F)c2)c2ccccc12)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 1/20 0.45
BRD4 O60885 1/20 0.42
TP53 P04637 4/20 0.42
THRB P10828 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ADAM17 P78536 1/20 0.40
UBE2M P61081 1/20 0.40
DCUN1D1 Q96GG9 1/20 0.40
TRPV4 Q9HBA0 1/20 0.39
POLB P06746 2/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
PTGER4 P35408 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335807 0.91 ADAM17 (0.40) MAPTSMN1; SMN2TP53MEN1KMT2A
SCHEMBL4343631 0.90 MAPT (0.44) MAPTSMN1; SMN2LMNABRD4TP53
SCHEMBL4341814 0.87 MAPT (0.48) MAPTSMN1; SMN2LMNABRD4MEN1
SCHEMBL4333072 0.83 MCL1 (0.41) MAPTSMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4333236 0.82 MEN1 (0.52) MAPTSMN1; SMN2LMNATP53MEN1
SCHEMBL13819344 0.81 ADAM17 (0.55) MAPTLMNAKMT2AADAM17ALDH1A1
SCHEMBL4348521 0.81 MGLL (0.48) MAPTSMN1; SMN2LMNATP53MEN1
SCHEMBL4332251 0.80 ADAM17 (0.47) MAPTTP53THRBADAM17ALDH1A1
SCHEMBL4341784 0.77 TP53 (0.49) MAPTSMN1; SMN2LMNATP53MEN1
SCHEMBL4338086 0.77 MEN1 (0.48) MAPTSMN1; SMN2LMNATHRBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 MAPT 4654/4885SMN1; SMN2 3054/4885LMNA 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.